Website maintenance took place on Thursday 30 April 2026. If you experience any issues, please contact us.
Notice for afamelanotide (Clinuvel Pharmaceuticals Ltd)
Active ingredients
afamelanotide
Sponsor
Date of review outcome
Lapse date
Type
Orphan drug
Dosage form(s)
Subcutaneous implant
Indication
For the treatment of erythropoietic porphyrias